Q-omics provides the consensus-scored SNORA24B profile across patient tissues and cancer cell-line models. SNORA24B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNORA24B is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SNORA24B RNA expression shows 6,484 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, KIRC, and STAD as cancer lineages where SNORA24B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA24B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA24B survival associations across molecular data types. SNORA24B RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA24B RNA expression–survival associations across cancer types. High SNORA24B expression shows unfavorable associations in UVM, LIHC, UCEC, KIRP, THYM and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SNORA24B RNA expression.
This table summarizes SNORA24B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA24B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA24B shows higher tumor expression in KIRC, HNSC, STAD, LIHC, LUSC and LUAD. The KIRC box plot shows higher SNORA24B RNA expression in tumor versus normal tissue (log2 FC = +0.133, t-test p = .003).
This table shows molecular features associated with SNORA24B in patient tissues and cancer cell lines. In patient samples, SNORA24B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
